Published in Hospital Law Weekly, February 22nd, 2007
Novogen had alleged that certain menopause products sold by Sante infringed Novogen's Canadian patent for health supplements containing isoflavones. (Patent No. 2136233).
In addition to an undisclosed monetary settlement, Sante has entered into a licensing agreement with Novogen. This agreement grants Sante a license under Canadian Patent No. 2136233 and will enable Sante to continue to manufacture and sell certain menopause supplements containing isoflavones derived from sources other than soy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.